Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-02-23 00:00:00 ET · period of report 2023-02-21 · accession 0001209191-23-012321 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-23 | 2023-02-21 | RXRX | Borgeson Blake | Dir | S - Sale | $7.73 | -8,885 | 7.59M | -0.1% | -$68.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-02-21 | S | D | 8,885 | $7.73 | 7,594,057 | D | — | — | (F2) The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.66 to $7.97 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. |